Sitagliptin
This once-daily pill helps control blood sugar in type 2 diabetes by preventing the breakdown of incretin hormones that naturally stimulate insulin release after eating. It works gently without causing significant low blood sugar on its own and is often combined with metformin or other diabetes medications.
Molekularmasse
407,3140 g/mol
LogP
0,70
TPSA
77,00 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Arzneimittelklassen
Wirkmechanismus
DPP-4 inhibitor increasing incretin levels.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
DPP-4 inhibitor increasing incretin levels.
2D-Struktur
Cite this structure
Embed this structure
SMILES
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F
InChI
InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
Molecular Formula
C16H15F6N5O
HBD / HBA
1 / 10
Rotierbare Bindungen
4
Schwere Atome
28
Combining tirzepatide (dual GIP/GLP-1 agonist) with sitagliptin (DPP-4 inhibitor) produces overlapping incretin-based mechanisms with additive hypoglycaemia risk and no meaningful additional benefit over either agent alone.
Sitagliptin modestly increases digoxin exposure through inhibition of P-glycoprotein-mediated renal tubular secretion, though the effect is unlikely to be clinically significant at therapeutic digoxin doses.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
This once-daily pill helps control blood sugar in type 2 diabetes by preventing the breakdown of incretin hormones that naturally stimulate insulin release after eating. It works gently without causing significant low blood sugar on its own and is often combined with metformin or other diabetes medications.
DPP-4 inhibitor increasing incretin levels.
Key pharmacokinetic parameters for Sitagliptin: Half-life: 12.4 hours.
Yes, Sitagliptin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1422. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 4369359. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sitagliptin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sitagliptin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sitagliptin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sitagliptin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sitagliptin"></drugfyi-drug>